Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

[1]  T. Graeber,et al.  Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. , 2019, Cell reports.

[2]  T. Graeber,et al.  Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. , 2017, Cancer discovery.

[3]  C. Andrewes,et al.  Virus interference. I. The interferon , 2017 .

[4]  J. Wargo,et al.  Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy , 2016, Cell.

[5]  T. Graeber,et al.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.

[6]  David J. Arenillas,et al.  JASPAR 2016: a major expansion and update of the open-access database of transcription factor binding profiles , 2015, Nucleic Acids Res..

[7]  Ryan Miller,et al.  WikiPathways: capturing the full diversity of pathway knowledge , 2015, Nucleic Acids Res..

[8]  T. Graeber,et al.  Innate resistance of PD-1 blockade through loss of function mutations in JAK resulting in inability to express PD-L1 upon interferon exposure , 2015, Journal of Immunotherapy for Cancer.

[9]  Antoni Ribas,et al.  Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance , 2015, Cell.

[10]  A. Ribas.  Adaptive Immune Resistance: How Cancer Protects from Immune Attack. , 2015, Cancer discovery.

[11]  J. Lunceford,et al.  Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. , 2015 .

[12]  Nuno Nunes,et al.  PathVisio 3: An Extendable Pathway Analysis Toolbox , 2015, PLoS Comput. Biol..

[13]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[14]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[15]  Antoni Ribas,et al.  Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma , 2014, Clinical Cancer Research.

[16]  T. Graeber,et al.  COX‐2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors , 2014, Molecular oncology.

[17]  L. Ivashkiv,et al.  Regulation of type I interferon responses , 2013, Nature Reviews Immunology.

[18]  Cole Trapnell,et al.  TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions , 2013, Genome Biology.

[19]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[20]  E. Jacobson,et al.  Novel Variant of Thyroglobulin Promoter Triggers Thyroid Autoimmunity through an Epigenetic Interferon α-modulated Mechanism* , 2011, The Journal of Biological Chemistry.

[21]  P. Dobrzanski,et al.  A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis , 2011, Arthritis research & therapy.

[22]  B. Saha,et al.  Gene modulation and immunoregulatory roles of interferon gamma. , 2010, Cytokine.

[23]  M. Wasik,et al.  Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1) , 2008, Proceedings of the National Academy of Sciences.

[24]  R. König,et al.  A probability-based approach for the analysis of large-scale RNAi screens , 2007, Nature Methods.

[25]  Erik van Nimwegen,et al.  SwissRegulon: a database of genome-wide annotations of regulatory sites , 2006, Nucleic Acids Res..

[26]  Lieping Chen,et al.  Interferon regulatory factor‐1 is prerequisite to the constitutive expression and IFN‐γ‐induced upregulation of B7‐H1 (CD274) , 2006, FEBS letters.

[27]  Patrick J. Paddison,et al.  Second-generation shRNA libraries covering the mouse and human genomes , 2005, Nature Genetics.

[28]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Lieping Chen,et al.  Constitutive and Inducible Expression of B 7 Family of Ligands by Human Airway Epithelial Cells , 2005 .

[30]  Giovanna Lombardi,et al.  Type I interferons and the innate immune response--more than just antiviral cytokines. , 2005, Molecular immunology.

[31]  L. Platanias.  Mechanisms of type-I- and type-II-interferon-mediated signalling , 2005, Nature Reviews Immunology.

[32]  R. Schreiber,et al.  IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. , 2005, Cancer research.

[33]  Yulan Qing,et al.  Alternative Activation of STAT1 and STAT3 in Response to Interferon-γ* , 2004, Journal of Biological Chemistry.

[34]  K. Schroder,et al.  Interferon- : an overview of signals, mechanisms and functions , 2004 .

[35]  J. S. Gutkind,et al.  Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. , 2003, Cancer research.

[36]  P. Loke,et al.  PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[37]  F. Netter,et al.  Supplemental References , 2002, We Came Naked and Barefoot.

[38]  D. Aaronson,et al.  A Road Map for Those Who Don't Know JAK-STAT , 2002, Science.

[39]  G. Zhu,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[40]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[41]  J. Kappes,et al.  Safety Considerations in Vector Development , 2001, Somatic cell and molecular genetics.

[42]  D. Pardoll,et al.  B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells , 2001, The Journal of experimental medicine.

[43]  D. J. Van Den Berg,et al.  CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors. , 1999, Experimental hematology.

[44]  R. Prywes,et al.  Serum-Induced Expression of the cdc25AGene by Relief of E2F-Mediated Repression , 1999, Molecular and Cellular Biology.

[45]  R. Schreiber,et al.  Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .

[46]  O. Colamonici,et al.  The type-I interferon receptor. The long and short of it. , 1996, Cytokine & growth factor reviews.

[47]  B. Cohen,et al.  The human interferon-αgb receptor: Characterization and molecular cloning , 1994 .

[48]  J. Darnell,et al.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.

[49]  B. Cohen,et al.  The human interferon α β receptor: Characterization and molecular cloning , 1994, Cell.

[50]  M. Fellous,et al.  A protein tyrosine kinase in the interferon α β signaling pathway , 1992, Cell.

[51]  T. Decker,et al.  Cytoplasmic activation of GAF, an IFN‐gamma‐regulated DNA‐binding factor. , 1991, The EMBO journal.

[52]  J. Darnell,et al.  Overlapping elements in the guanylate-binding protein gene promoter mediate transcriptional induction by alpha and gamma interferons , 1991, Molecular and cellular biology.

[53]  J. Darnell,et al.  Two interferon-induced nuclear factors bind a single promoter element in interferon-stimulated genes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[54]  G. Stark,et al.  α-Interferon-induced transcription of HLA and metallothionein genes containing homologous upstream sequences , 1985, Nature.

[55]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[56]  R. Tiwari,et al.  Who is (are) the author(s) , 1977 .